Pacira Pharmaceuticals Stock Price and Value Analysis

Should you buy Pacira Pharmaceuticals stock? (NasdaqGS:PCRX). Let's see how it does in our automated value investing analysis system.

  • This company is solid.
  • This company has fluctuating growth.
  • This company is not making money.
  • This stock looks overpriced.
  • This company pays no dividend.

PCRX Free Cash Flow Trend

Hmm, we can't give any reliable projection for Pacira Pharmaceuticals's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

Free Cash Flow trendline for PCRX
Free Cash Flow trendline for Pacira Pharmaceuticals

Inside the PCRX Numbers

PCRX Price
(Pacira Pharmaceuticals stock price per share)
[?] PE Ratio versus Sector 931% higher than other Healthcare stocks
[?] PE Ratio versus Industry 317% higher than other Drug Manufacturers - Specialty & Generic stocks
[?] Cash Yield -0.03%
[?] Free Cash Flow Jitter 34%

Is Pacira Pharmaceuticals Stock on Sale?

Based on our analysis, we believe that you should not buy Pacira Pharmaceuticals right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy PCRX Stock?

Does Pacira Pharmaceuticals have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.